Upfront Briefing
Roche gave the tape a clean regulatory marker, with FDA Priority Review for giredestrant and a 30 November 2026 decision date now on the calendar. Elsewhere, Abivax delivered the classic biotech split-screen: Phase 3 UC efficacy that supports a filing case, plus cancer cases that keep the safety debate very much open.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,600.0 |
0.3% |
10.8% |
| Nasdaq 100 |
30,513.9 |
0.6% |
21.1% |
| Russell 2000 |
2,905.8 |
(0.5%) |
15.8% |
| Healthcare (XLV) |
147.8 |
(1.1%) |
(4.9%) |
| Biotech (XBI) |
133.6 |
(2.2%) |
10.0% |
| Nasdaq Biotech (NBI) |
5,878.6 |
(1.9%) |
3.0% |
| Clinical Trials (BBC) |
43.9 |
(1.6%) |
16.5% |
|
- Healthcare and biotech bucked the risk-on tape — XLV (1.1%), XBI (2.2%), NBI (1.9%) — as the ASCO 2026 wrap-up drove rotation and profit-taking across oncology names (RevMed and Akeso plenary readouts), with safety-signal headlines, including Abivax's post-market drop on reported cancer cases, weighing on sentiment.
- The broader tape closed at record highs — Nasdaq 100 0.6%, S&P 500 0.3% — led by Nvidia (up ~6%) on its new RTX Spark PC chip unveiled at Computex, with optimism on continuing U.S.–Iran talks offsetting an oil spike tied to Strait of Hormuz disruption.
- Market data: U.S. cash close Monday, 1 June 2026.
The Big 3
|
1
|
Roche wins FDA Priority Review for giredestrant NDA
|
- Giredestrant, an oral SERD, won FDA acceptance with Priority Review in ER-positive, HER2-negative, stage I-III early breast cancer, with a decision due 30 November 2026.
-
Why it matters: The filing rests on lidERA, where adjuvant giredestrant cut the risk of invasive recurrence or death by 30% versus standard endocrine therapy in ER+/HER2− early disease. Priority Review puts giredestrant on track to be the first oral SERD into the adjuvant setting — the largest ER+ prize, since ~70% of breast cancers are ER+ and most are caught early — ahead of AstraZeneca's camizestrant and Lilly's imlunestrant chasing the same early-stage market. The 30 November decision is the catalyst; the read-through is potential displacement of generic anastrozole/tamoxifen as the adjuvant backbone.
- Source: PR
|
|
2
|
Abivax posts Phase 3 obefazimod UC maintenance data
|
- Obefazimod posted Phase 3 maintenance data in moderately to severely active ulcerative colitis that support a registration case, but reported cancer cases clouded the setup.
-
Why it matters: In the 44-week ABTECT maintenance trial (N=580), both doses hit the primary endpoint — clinical remission of 50.8% (25 mg) and 51.3% (50 mg) vs 10.4% on placebo (placebo-adjusted ∆~40%, p<0.0001) — which Leerink flagged as the highest placebo-adjusted remission yet in a long-term UC study, supporting a late-Q4 2026 NDA. But shares sold off after hours as Abivax disclosed a handful of cancer cases among treated patients. That split is the story: approval probability looks high, yet a malignancy signal in a chronic, lifelong-dosing indication caps peak-sales math until longer safety follow-up resolves it.
-
Source:
STAT
-
More:
PR
|
|
3
|
The tape's verdict on ASCO's plenary: RAS and PD-1/VEGF re-rate
|
- Revolution Medicines (RVMD) gapped up ~20% on the data and held those gains into Monday's session amid a wave of analyst target hikes (Oppenheimer to $195); Summit (SMMT) added ~3.6% on ivonescimab's HARMONi-6 OS win.
-
Why it matters: The weekend's two plenary readouts (covered Monday) are now repricing whole sub-sectors: RVMD's move re-rates the RAS(ON)/pan-RAS complex and raises the bar for covalent KRAS peers, while ivonescimab's head-to-head OS win over a PD-1 tightens comps across the PD-1/VEGF bispecific field. The pushback is the same for both: Jefferies' Faisal Khurshid flagged that the key investor question is whether single-region (largely China-run) data replicate in US/EU registration trials — keeping the COINS Act and FDA single-country-data overhang squarely on the ex-China commercial thesis.
- Source: BioBucks (Mon)
|
Everything Else that broke
- Greywolf’s oral ERAP1 inhibitor GRWD5769 posted 13-36% ORRs across six solid tumor types. — PR
- CorrectSequence reported 15-month VOC-free follow-up for base-editing therapy CS-206 in sickle cell disease. — PR
- Santhera won South Korea orphan and GIFT designations for AGAMREE in Duchenne muscular dystrophy. — PR
- Inventiva requested a temporary trading halt in Paris ahead of pending material news. — PR
- Bavarian Nordic launched the final 2026 buyback tranche for up to DKK 500M. — PR
- Ranok shared interim Phase 1 data for KRAS G12D inhibitor RNK08954 in metastatic NSCLC. — PR
- Genomics launched Mystra AI for target discovery, validation and BD&L workflows. — PR
- Nanobiotix joined the Euronext Tech Leaders Index, adding a bit more visibility and passive potential. — PR
- BrainStorm added former FDA leader Peter Pitts to its board for a renewed ALS push. — BioSpace
- OXB is hosting a capital markets event for investors in its cell and gene therapy CDMO story. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Agios licensed exclusive global rights to Oscotec’s SYK inhibitor cevidoplenib, paying $25M upfront with additional development, regulatory and commercial milestones plus tiered royalties. — PR
VC / Private Financings
- Oak Hill Bio raised a $32.5M Series A to push rugonersen into a pivotal Angelman syndrome study; the round was co-led by Balyasny Asset Management, venBio and Janus Henderson Investors, with participation from KCap Biotechnology Fund. — PR
- Waypoint Bio closed a $20M Series A led by Amplify Partners to advance AI-designed CAR-T work in solid tumors. — Business Wire
IPOs / Follow-Ons
- Rallybio and Avenzo agreed to merge, paired with a $215M concurrent private placement backed by new investors including Blackstone and existing backers including OrbiMed. — Business Wire
Academic Corner - Selection of human hematopoietic stem cells bearing the intended functional edit by transient AND-gate reporters. — Nature Biotech
- Downplaying toxicities in cancer drug trials is not acceptable. — Nature Medicine
- Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial. — Nature Medicine
- Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. — Nature Medicine
- SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. — Nature Medicine
|
